Pentostatin Plus Cyclophosphamide Safely and Effectively Prevents Immunotoxin Immunogenicity in Murine Hosts

Purpose: The success of immunotoxin therapy of cancer is limited by host production of neutralizing antibodies, which are directed toward the Pseudomonas exotoxin A (PE) component. In this proof-of-principle study using a well-established murine model, we hypothesized that a newly developed immune depletion regimen consisting of pentostatin plus cyclophosphamide would abrogate anti-immunotoxin reactivity. Experimental Design: BALB/c hosts were injected weekly with recombinant immunotoxin (RIT) SS1P, which is an antimesothelin Fv antibody fragment genetically fused to a 38 kDa portion of PE, and has been evaluated in clinical trials. Experimental cohorts received induction chemotherapy consisting of pentostatin (P) plus cyclophosphamide (C) prior to initial RIT exposure; some cohorts received further maintenance PC therapy of varying intensity just prior to each weekly RIT challenge. Cohorts were monitored for T, B, myeloid cell depletion, and for total anti-SS1P antibody (Ab) formation. Results: Controls uniformly developed anti-SS1P Ab after the third RIT exposure. Induction PC therapy reduced the frequency of hosts with anti-SS1P Ab. Abrogation of antibody generation was improved by maintenance PC therapy: nearly 100% of recipients of intensive PC maintenance were free of anti-SS1P Ab after 9 weekly RIT doses. The most effective PC regimen yielded the greatest degree of host B-cell depletion, moderate T-cell depletion, and minimal myeloid cell depletion. Conclusions: Induction and maintenance PC chemotherapy safely prevented anti-immunotoxin antibody formation with uniform efficacy. These data suggest that immunotoxin therapy might be used in combination with pentostatin plus cyclophosphamide chemotherapy to improve the targeted therapy of cancer. Clin Cancer Res; 17(11); 3697–705. ©2011 AACR.

[1]  Mitchell Ho,et al.  Mesothelin Expression in Human Lung Cancer , 2007, Clinical Cancer Research.

[2]  James J. Vincent,et al.  Characterization of the B Cell Epitopes Associated with a Truncated Form of Pseudomonas Exotoxin (PE38) Used to Make Immunotoxins for the Treatment of Cancer Patients1 , 2006, The Journal of Immunology.

[3]  V. Arruda,et al.  Strategies to modulate immune responses: a new frontier for gene therapy. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[4]  J. Sprent,et al.  The role of host T cell subsets in bone marrow rejection directed to isolated major histocompatibility complex class I versus class II differences of bm1 and bm12 mutant mice. , 1994, Transplantation.

[5]  J. Armitage,et al.  Lymphodepleting effects and safety of pentostatin for nonmyeloablative allogeneic stem-cell transplantation. , 2003, Transplantation.

[6]  A. Frankel,et al.  Bioengineering a Unique Deimmunized Bispecific Targeted Toxin That Simultaneously Recognizes Human CD22 and CD19 Receptors in a Mouse Model of B-Cell Metastases , 2010, Molecular Cancer Therapeutics.

[7]  V. Kapoor,et al.  Graft rejection as a Th1-type process amenable to regulation by donor Th2-type cells through an interleukin-4/STAT6 pathway. , 2008, Blood.

[8]  Mitchell Ho,et al.  Releasable PEGylation of mesothelin targeted immunotoxin SS1P achieves single dosage complete regression of a human carcinoma in mice. , 2007, Bioconjugate chemistry.

[9]  Mitchell Ho,et al.  New Monoclonal Antibodies to Mesothelin Useful for Immunohistochemistry, Fluorescence-Activated Cell Sorting, Western Blotting, and ELISA , 2005, Clinical Cancer Research.

[10]  I. Pastan,et al.  Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[11]  Y. Beguin,et al.  Nonmyeloablative allogeneic hematopoietic stem cell transplantation. , 2002, Journal of hematotherapy & stem cell research.

[12]  I. Pastan,et al.  A Recombinant Immunotoxin Targeting CD22 With Low Immunogenicity, Low Nonspecific Toxicity, and High Antitumor Activity in Mice , 2010, Journal of immunotherapy.

[13]  W. Grizzle,et al.  A phase I trial of the single-chain immunotoxin SGN-10 (BR96 sFv-PE40) in patients with advanced solid tumors. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[14]  Masanori Onda,et al.  Reducing the immunogenicity of protein therapeutics. , 2009, Current drug targets.

[15]  M. Grever,et al.  Pentostatin in steroid-refractory acute graft-versus-host disease. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Marcia Stickler,et al.  Elimination of an Immunodominant CD4+ T Cell Epitope in Human IFN-β Does Not Result in an In Vivo Response Directed at the Subdominant Epitope , 2004, The Journal of Immunology.

[17]  A. S. A. Don,et al.  Recent clinical trials of mTOR-targeted cancer therapies. , 2011, Reviews on recent clinical trials.

[18]  R. Storb,et al.  Review of “Minitransplantation”: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation , 2003, International journal of hematology.

[19]  A. Frankel.  Immunotoxin therapy of cancer. , 1993, Oncology.

[20]  A. Oseroff,et al.  Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  Hao Wang,et al.  PE38KDEL-loaded anti-HER2 nanoparticles inhibit breast tumor progression with reduced toxicity and immunogenicity , 2009, Breast Cancer Research and Treatment.

[22]  S. Steinberg,et al.  Host T cells affect donor T cell engraftment and graft-versus-host disease after reduced-intensity hematopoietic stem cell transplantation. , 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[23]  R. Gress,et al.  Reconstitution of the lymphocyte compartment after lymphocyte depletion: A key issue in clinical immunology , 2005, European journal of immunology.

[24]  I. Pastan,et al.  Monoclonal Antibody K1 Reacts With Epithelial Mesothelioma but not With Lung Adenocarcinoma , 1992, The American journal of surgical pathology.

[25]  J. Serody,et al.  Preformed antibody, not primed T cells, is the initial and major barrier to bone marrow engraftment in allosensitized recipients. , 2007, Blood.

[26]  I. Pastan,et al.  Frequent expression of the tumor antigen cak1 in squamous‐cell carcinomas , 1992, International journal of cancer.

[27]  R. Kobayashi,et al.  Treatment of adenosine deaminase deficiency with polyethylene glycol-modified adenosine deaminase. , 1987, The New England journal of medicine.

[28]  G. Gorgun,et al.  A novel reduced intensity regimen for allogeneic hematopoietic stem cell transplantation associated with a reduced incidence of graft-versus-host disease , 2004, Bone Marrow Transplantation.

[29]  J. Cameron,et al.  Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[30]  I. Pastan,et al.  Phase I Study of SS1P, a Recombinant Anti-Mesothelin Immunotoxin Given as a Bolus I.V. Infusion to Patients with Mesothelin-Expressing Mesothelioma, Ovarian, and Pancreatic Cancers , 2007, Clinical Cancer Research.

[31]  W. Wilson,et al.  Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  P. Daddona,et al.  Purinogenic immunodeficiency diseases: selective toxicity of deoxyribonucleosides for T cells. , 1978, Proceedings of the National Academy of Sciences of the United States of America.

[33]  I. Pastan,et al.  Removal of B cell epitopes as a practical approach for reducing the immunogenicity of foreign protein-based therapeutics. , 2009, Advanced drug delivery reviews.

[34]  Ira Pastan,et al.  An immunotoxin with greatly reduced immunogenicity by identification and removal of B cell epitopes , 2008, Proceedings of the National Academy of Sciences.

[35]  Justin Taylor,et al.  The pentostatin plus cyclophosphamide nonmyeloablative regimen induces durable host T cell functional deficits and prevents murine marrow allograft rejection. , 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[36]  E. Giblett,et al.  Adenosine-deaminase deficiency in two patients with severely impaired cellular immunity. , 1972, Lancet.

[37]  Nihal Ahmad,et al.  Dose translation from animal to human studies revisited , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[38]  Jingli Zhang,et al.  Anti–Mesothelin Immunotoxin SS1P in Combination with Gemcitabine Results in Increased Activity against Mesothelin-Expressing Tumor Xenografts , 2007, Clinical Cancer Research.

[39]  W. Wilson,et al.  Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  C. Mackall,et al.  T-cell regeneration after bone marrow transplantation: differential CD45 isoform expression on thymic-derived versus thymic-independent progeny. , 1993, Blood.

[41]  I. Pastan,et al.  Phase I Trial of Continuous Infusion Anti-Mesothelin Recombinant Immunotoxin SS1P , 2009, Clinical Cancer Research.

[42]  I. Pastan,et al.  Isolation of a high-affinity stable single-chain Fv specific for mesothelin from DNA-immunized mice by phage display and construction of a recombinant immunotoxin with anti-tumor activity. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[43]  A. Spiers,et al.  Hairy-cell leukemia: induction of complete remission with pentostatin (2'-deoxycoformycin). , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  W. Wilson,et al.  Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. , 2001, The New England journal of medicine.

[45]  P. Pereira,et al.  T Cell‐Dependent B Cell Activation , 1984, Immunological reviews.

[46]  I. Pastan,et al.  Pretreatment with Rituximab Does Not Inhibit the Human Immune Response against the Immunogenic Protein LMB-1 , 2004, Clinical Cancer Research.

[47]  R. Champlin,et al.  Non myeloablative "mini transplants". , 1999, Cancer treatment and research.

[48]  D. Scheinberg,et al.  Pentostatin and cyclophosphamide: an effective new regimen in previously treated patients with chronic lymphocytic leukemia. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.